Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml

Journal of Surgical Oncology

Volumn 96, Issue 1, 2007, Pages 54-61

  Zhigang, Zhao ^a   Jieming, Liu ^a   Su, Li ^a   Weintu, Shen ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Insulin like growth factor binding protein 3 (IGFBP 3); Insulin like growth factor I (IGF I); Prostate carcinoma (PCa); Prostate specific antigen (PSA)

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY;

AGED; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34347331093     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20784     Document Type: Article

References (31)

1. Diamandis EP: Induction of prostate-specific antigen expression by synthetic progestins in patients with prostate and breast cancer. Mayo Clin Proc 1998;73:706-707.
2. Scorilas A, Yu H, Soosaipillai AR, et al.: Comparision of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. Clin Chim Acta 2000;292:127-138.
3. Polascik TJ, Oesterling JE, Partin AW: Prostate specific antigen: A decade of discovery-what we have learned and where we are going. J Urol 1999;162:293-306.
4. Stenman U, Finne P, Zhang W, et al.: Prostate-specific antigen and other prostate cancer markers. Urology 2000;56:893-898.
5. Klingler HC, Woo H, Rosario D, et al.: The value of prostate specific antigen (PSA) density and free: Total PSA ratio in selecting patients with a normal digital rectal examination and intermediate total PSA levels for further investigation. BJU Int 1998;82:393-397.
6. Pollack M: Insulin-like growth factors and prostate cancer. Epidemiol Rev 2001;23:59-66.
7. Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-1489.
8. Dunn SE, Kari FW, French J, et al.: Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997;57:4667-4672.
9. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279:563-566.
10. Mantzoros CS, Tzonou A, Signorello LB, et al.: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115-1118.
11. Wolk A, Mantzoros CS, Andersson SO, et al.: Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998;90:911-915.
12. Stattin P, Bylund A, Rinal S, et al.: Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: A prospective study. J Natl Cancer Inst 2000;92:1910-1917.
13. Harman SM, Metter EJ, Blackman MR, et al.: Baltimore Longitudinal Study on Aging. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000;85:4258-4265.
14. Chokkalingam AP, Pollak M, Fillmore CM, et al.: Insulin-like growth factors and prostate cancer: A population-based case-control study in China. Cancer Epidemiol Biomarkers Prevent 2001;10:421-427.
15. Oliver SE, Gunnell D, Donovan J, et al.: Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Int J Cancer 2004;108:887-892.
16. Khosravi J, Diamandi A, Mistry J, et al.: Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab 2001;86:694-699.
17. Djavan B, Bursa B, Seitz C, et al.: Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology 1999;54:603-606.
18. Chen C, Lewis SK, Voigt L, et al.: Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 2005;103:76-84.
19. Wolk A, Anderson SO, Mantzoros CS, et al.: Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening? Lancet 2000;356:1902-1903.
20. Delong ER, Delong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988;44:837-845.
21. Grimberg A, Cohen P: Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000;183:1-9.
22. Torring N, Vinter-Jensen L, Pedersen SB, et al.: Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate. J Urol 1997;158:222-227.
23. Koliakos G, Chatzivasiliou D, Dimopoulos T, et al.: The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer. Dis Markers 2000;16:143-146.
24. Finne P, Auvinen A, Koistinen H, et al.: Insulin-like growth factor-I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 2000;85:2744-2747.
25. Miyata Y, Sakai H, Hayashi T, et al.: Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 2003;54:125-132.
26. Cutting CW, Hunt C, Nisbet JA, et al.: Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int 1999;83:996-999.
27. Ismail AH, Pollak M, Behlouli H, et al.: Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. J Urol 2002;168:2426-2430.
28. Oliver SE, Hollyb J, Petersc TJ, et al.: Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. Urology 2004;64:317-322.
29. Janssen JA, Wildhagen MF, Ito K, et al.: Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: Results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J Clin Endocrinol Metab 2004;89:4391-4396.
30. Kurek R, Tunn UW, Eckar O, et al.: The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer. BJU Int 2000;85:125-129.
31. Scorilas A, Plebani M, Mazza S, et al.: Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and % free PSA. Prostate 2003;54:220-229.